Article contents
Rasagiline and venlafaxine: The serotonin syndrome
Published online by Cambridge University Press: 23 March 2020
Abstract
Rasagiline is a highly potent irreversible monoamine oxidase (MAO)-B inhibitor, antiparkinsonian drug that may be used with caution in patients treated with antidepressant drugs because of the possible appearance of severe adverse effects. It is presented the case report of a woman treated with rasagiline and venlafaxine that presents confusion and a serotonin syndrome. Pathogenesis, physiopathology and treatment are discussed. Growing evidence suggests that Parkinson disease and depression are linked. Antidepressant drugs and PD treatment should be used with caution because of possible drug interaction.
The authors have not supplied their declaration of competing interest.
- Type
- e-Poster Viewing: Psychopharmacology and pharmacoeconomics
- Information
- European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S759
- Copyright
- Copyright © European Psychiatric Association 2017
- 1
- Cited by
Comments
No Comments have been published for this article.